Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menu

Search BMS Clinical Trials
BMS Recruiting Study icon

Recruiting

Trial ID CN012-0030  |   NCT06605950

A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants

Summary

  • Phase 1
  • Male and Female Gender icon
  • 19-90
    Age Range
  • 1
    Locations
  • BMS Recruiting Study icon
    Recruiting

Overview

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of multiple doses of KarXT + KarX-EC capsules versus KarXT capsules in healthy adult and elderly participants of Japanese ethnicity and to assess the effect of multiple doses of omeprazole on the exposure of xanomeline and trospium administered as KarXT + KarX-EC capsules in healthy adult participants.

print Print
email Email

Nearest Recruiting Site

Key Eligibility Criteria

Inclusion Criteria

Inclusion Criteria Icon img
  • Inclusion Criteria for Healthy Adult Japanese Participants (Group A):.
    1. Healthy adult participants must be 19 to 55 years of age, inclusive.
      1. Both participant's biological parents are of ethnic Japanese ancestry. Participants must be first generation Japanese.
        1. Must have a body mass index (BMI) of 18.0 to 32.0 kg/m2 (inclusive), at the time of signing the ICF.
          1. Must have an estimated glomerular filtration rate (eGFR) of ≥ 90 mL/min/1.73m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation at the screening visit. One repeat measurement is allowed.
          2. Inclusion Criteria for Healthy Elderly Japanese Participants (Groups B and C):.
            1. Healthy elderly participants must be 56 to 90 years of age, inclusive.
              1. Both participant's biological parents are of ethnic Japanese ancestry. Participants must be first generation Japanese.
                1. Must have a BMI ≥ 18.0 and ≤ 35.0 kg/m2 (inclusive), at the time of signing the ICF.
                  1. Must have an eGFR of > 60 mL/min/1.73m2 by the CKD-EPI equation at the screening visit. One repeat measurement is allowed.
                  2. Inclusion Criteria for Healthy Adult Participants (Groups D):.
                    1. Healthy adult participants must be 19 to 55 years of age, inclusive.
                      1. Participants with any ethnicity can be included.
                        1. Must have a BMI of 18.0 to 32.0 kg/m2 (inclusive), at the time of signing the ICF.
                          1. Must have an eGFR of ≥ 90 mL/min/1.73m2 by the CKD-EPI equation at the screening visit. One repeat measurement is allowed.

                          Exclusion Criteria

                          Exclusion Criteria Icon
                          • Exclusion Criteria for All Participants (Groups A, B, C, and D):.
                            1. Participant is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
                              1. History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.
                                1. Participant has a history of syncope and/or symptomatic orthostatic hypotension in the year prior to Day 1.
                                  1. History of cancer that has not been in full remission for >5 years (except basal cell skin cancer or squamous cell skin cancer with history of curative treatment and no recurrence for > 1 year prior to the screening visit).
                                  Additional Information *
                                  • Other protocol-defined Inclusion/Exclusion criteria apply.

                                    Treatment Options

                                    Study Arms

                                    ASSIGNED INTERVENTION

                                    Study Arms

                                    Experimental: Group A

                                    ASSIGNED INTERVENTION
                                    • Drug: KarXT, Placebo

                                    Study Arms

                                    Experimental: Group B

                                    ASSIGNED INTERVENTION
                                    • Drug: KarXT, Placebo

                                    Study Arms

                                    Experimental: Group C

                                    ASSIGNED INTERVENTION
                                    • Drug: KarXT, KarX-EC, Placebo

                                    Study Arms

                                    Experimental: Group D

                                    ASSIGNED INTERVENTION
                                    • Drug: KarXT, KarX-EC, Omeprazole
                                    Take the first step to see if you Match to a Clinical Trial – Check Your Eligibility
                                    Check Your Eligibility
                                    Answer some questions about Your health to see if you may match to this trial
                                    Match to a Trial
                                    If you are a match, click on the study to see the list of study site locations
                                    Select a Study Site Location
                                    Select a study site location that is convenient for you
                                    Register
                                    Provide your contact details for the study site to connect with you.

                                    Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you